Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Cancer

Volumn 106, Issue 1, 2006, Pages 106-111

  Hitt, Ricardo ^a   Amador, Maria L ^a   Quintela Fandino, Miguel ^a   Jimeno, Antonio ^a   Del Val, Olga ^a   Hernando, Susana ^a   Cortes Funes, Hernan ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Head and neck carcinoma; Recurrent metastatic tumor; Squamous cell carcinoma; Weekly docetaxel

Indexed keywords

CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; FLUOROURACIL; PACLITAXEL; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD CELL COUNT; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONJUNCTIVITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HUMAN; KIDNEY FUNCTION; LEUKOPENIA; MALE; METASTASIS; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; ONYCHOLYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; THROMBOCYTOPENIA; TIME SERIES ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 29744438809     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21579     Document Type: Article

References (25)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin. 2002;52:23-47.
2. Kotwall C, Sako K, Zack MS, Rao U, Bakamjian V, Shedd DD. Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg. 1987;154:439-442.
3. Zbaeren P, Lehmann W. Frequency and sites of distant metastases in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1987;113:762-764.
4. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer [review]. N Engl J Med. 2001;345:1890-1900.
5. Armand JP, Couteau C. Chemotherapy in head and neck cancer. Eur J Cancer. 1995;31A:819-822.
6. Liggett W Jr., AA Forastiere. Chemotherapy advances in head and neck oncology. Semin Surg Oncol. 1995;11:265-271.
7. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091-2098.
8. Jacobs C, Lyman G, Velez-Garcia E, et al. A Phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10:257-263.
9. Schrijvers D, Johnson J, Jiminez U, et al. Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group. J Clin Oncol. 1998;16:1054-1059.
10. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992;10:1245-1251.
11. [No authors listed.] A Phase III randomised trial of cisplatinum, methotrextate, cis-platinum + methotrexate and cis-platinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. Br J Cancer. 1990;61:311-315.
12. Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A Phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994;5:521-526.
13. Forastiere AA, Leong T, Rowinsky E, et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol. 2001;19:1088-1095.
14. Calais G, Bardet E, Sire C, et al. Radiotherapy with concomitant weekly docetaxel for Stage III/IV oropharynx carcinoma. Results of the 98-02 GORTEC Phase II trial. Int J Radiat Oncol Biol Phys. 2004;58:161-166.
15. Dreyfuss AI, Clark JE, Morris CM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol. 2996;14:1672-1678.
16. Catimel G, Verweij J, Mattijssen V, et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol. 1994;5:533-537.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
18. Thall PF, Simon R, Ellenberg SS. A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics. 1989;45:537-547.
19. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958;53:447-481.
20. D'hondt R, Paridaens R, Wildiers H, et al. Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a Phase II study. Anticancer Drugs. 2004;15:341-346.
21. Aihara T, Kim Y, Takatsuka Y. Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol. 2002;13:286-292.
22. Kouroussis C, Agelaki S, Mavroudis D, et al. A dose escalation study of weekly docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2002;46:488-492.
23. Hainsworth JD, Burris HA 3rd, Greco FA. Weekly administration of docetaxel (Taxotere): summary of clinical data. Semin Oncol. 1999;26(3 Suppl 10):19-24.
24. Hong WK, Schaefer S, Issell B, et al. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer. 1983;52:206-210.
25. Grose WE, Lehan DE, Dixon DO, Fletcher WS, Stuckey WJ. Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: a Southwest Oncology Group Study. Cancer Treat Rep. 1985;69:577-581.